{"altmetric_id":3258002,"counts":{"readers":{"mendeley":69,"citeulike":2,"connotea":0},"total":{"posts_count":1},"wikipedia":{"unique_users_count":1,"unique_users":["en:614750"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa6103cf058f610006e17","authors":["Xiao-Feng Le","Franz Pruefer","Robert C. Bast"],"doi":"10.4161\/cc.4.1.1360","endpage":"95","first_seen_on":"2015-02-03T05:43:40+00:00","issns":["1538-4101","1551-4005"],"issue":"1","journal":"Cell Cycle","last_mentioned_on":1417910205,"links":["http:\/\/dx.doi.org\/10.4161\/cc.4.1.1360"],"pubdate":"2014-10-28T00:00:00+00:00","publisher_subjects":[{"name":"Biochemistry And Cell Biology","scheme":"era"}],"scopus_subjects":["Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"87","subjects":["cellbiology"],"title":"HER2-targeting Antibodies Modulate the Cyclin-dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways","type":"article","volume":"4","mendeley_url":"http:\/\/www.mendeley.com\/research\/her2targeting-antibodies-modulate-cyclindependent-kinase-inhibitor-p27kip1-via-multiple-signaling-pa"},"altmetric_score":{"score":3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":3},"context_for_score":{"all":{"total_number_of_other_articles":4587710,"mean":5.3845268165588,"rank":1063158,"this_scored_higher_than_pct":64,"this_scored_higher_than":2954451,"rank_type":"exact","sample_size":4587710,"percentile":64},"similar_age_3m":{"total_number_of_other_articles":153152,"mean":8.8360002481212,"rank":44545,"this_scored_higher_than_pct":69,"this_scored_higher_than":106664,"rank_type":"exact","sample_size":153152,"percentile":69},"this_journal":{"total_number_of_other_articles":1729,"mean":2.0503657407407,"rank":142,"this_scored_higher_than_pct":71,"this_scored_higher_than":1236,"rank_type":"exact","sample_size":1729,"percentile":71},"similar_age_this_journal_3m":{"total_number_of_other_articles":111,"mean":2.2584727272727,"rank":12,"this_scored_higher_than_pct":89,"this_scored_higher_than":99,"rank_type":"exact","sample_size":111,"percentile":89}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":3,"Researcher":12,"Student  > Doctoral Student":4,"Student  > Ph. D. Student":16,"Student  > Postgraduate":2,"Student  > Master":12,"Other":5,"Student  > Bachelor":12,"Lecturer > Senior Lecturer":2,"Professor":1},"by_discipline":{"Engineering":2,"Medicine and Dentistry":14,"Chemistry":5,"Physics and Astronomy":1,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":28,"Business, Management and Accounting":1,"Biochemistry, Genetics and Molecular Biology":11,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"mendeley":{"US":1,"JP":1,"IT":2,"GB":1,"ZA":1,"ES":1}}},"posts":{"wikipedia":[{"title":"Trastuzumab","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=636952267#altmetric_citation_28","license":"public","citation_ids":[3258002,3258003],"posted_on":"2014-12-06T23:56:45+00:00","summary":"Trastuzumab (INN; trade names Herclon, Herceptin) is a monoclonal antibody that interferes with the HER2\/neu receptor.","page_url":"http:\/\/en.wikipedia.org\/?curid=614750","wiki_lang":"en","author":{"name":"187.165.85.105","url":"http:\/\/en.wikipedia.org\/wiki\/Special:Contributions\/187.165.85.105"}}]}}